Marathon petroleum stock price

In January, Pfizer said it expected acquired products to generate $20 billion in annual revenue by 2030. More recently, it announced the upcoming acquisition of Metsera and its experimental anti-obesity treatments. If either of Metsera's candidates continues to succeed in clinical studies, Pfizer's management team will have to significantly raise its 2030 revenue projection. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. Marathon Petroleum stock price advanced 0.9% to $150.76 after reports indicated strong throughput rates at its Gulf Coast facilities. Analysts note that efficient operations could enhance Q2 earnings momentum.